Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	64.5	73.87	1.32	60.71	53.42	126.95
Depreciation & Amortization	80.69	80.41	84.86	85.54	32.6	18.14
Other Amortization	-	-	0.53	2.11	17.5	16.58
Asset Writedown & Restructuring Costs	-	-	20.19	-	15	-
Loss (Gain) From Sale of Investments	-0.82	1.81	-0.12	3.22	0.07	-7.24
Loss (Gain) on Equity Investments	-	-	-	-12.89	-	-
Stock-Based Compensation	30.88	27.76	26.76	17.57	17.91	16.56
Other Operating Activities	-0.57	-9.85	-13.31	-15.2	-12.94	3.92
Change in Accounts Receivable	11.66	2.08	18.77	-16.37	3.87	-34.61
Change in Inventory	17.41	15.81	6.11	-17.86	-14.58	-10.12
Change in Accounts Payable	-14.79	-15.02	-36.29	-19.16	18.18	8.27
Change in Other Net Operating Assets	-1.9	-4.92	2.28	29.14	-3.9	-0.06
Operating Cash Flow	187.06	171.95	111.09	116.83	127.13	138.4
Operating Cash Flow Growth	20.79%	54.79%	-4.91%	-8.10%	-8.14%	-3.31%
Capital Expenditures	-1.2	-0.73	-0.55	-0.41	-2.05	-3.69
Cash Acquisitions	-	-	-	-	-311.69	-298.54
Investment in Securities	-81.74	-189.14	269.28	-216.25	231.82	267.53
Investing Cash Flow	-82.94	-189.87	268.73	-216.66	-81.91	-34.7
Short-Term Debt Issued	-	-	93	-	-	-
Long-Term Debt Issued	-	-	-	-	0.8	-
Total Debt Issued	-	-	93	-	0.8	-
Short-Term Debt Repaid	-	-	-93	-	-	-
Long-Term Debt Repaid	-	-	-402.5	-	-138.32	-0.8
Total Debt Repaid	-	-	-495.5	-	-138.32	-0.8
Net Debt Issued (Repaid)	-	-	-402.5	-	-137.52	-0.8
Issuance of Common Stock	15.66	14.91	6.61	12.42	7.1	4.36
Repurchase of Common Stock	-4.76	-2.72	-1.99	-	-	-
Other Financing Activities	-22.4	-	-	-22.9	-	-
Financing Cash Flow	-11.5	12.19	-397.88	-10.48	-130.42	3.56
Net Cash Flow	92.62	-5.72	-18.07	-110.31	-85.21	107.26
Free Cash Flow	185.87	171.23	110.53	116.41	125.08	134.71
Free Cash Flow Growth	20.35%	54.91%	-5.05%	-6.93%	-7.15%	-4.96%
Free Cash Flow Margin	27.94%	25.87%	18.19%	17.45%	21.57%	25.89%
Free Cash Flow Per Share	3.29	3.06	1.99	1.89	2.30	2.51
Cash Interest Paid	-	-	1.95	2.52	2.52	2.52
Cash Income Tax Paid	45.19	53.25	36.6	16.2	25.19	45.43
Levered Free Cash Flow	150.12	155.22	161.71	89.54	116.37	137.93
Unlevered Free Cash Flow	150.12	155.22	162.69	91.84	113.51	136.2
Change in Working Capital	12.38	-2.05	-9.14	-24.24	3.57	-36.52

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q